• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
PTX
Click for more information
0.00% 4.0¢

PRESCIENT THERAPEUTICS LIMITED - Charts / Financials

Market Cap $32.21M  ! watchlist Created with Sketch. Add to my watchlist

Prescient Therapeutics Limited is an Australia-based clinical-stage oncology company. The... Prescient Therapeutics Limited is an Australia-based clinical-stage oncology company. The Company is developing personalized medicine approaches to cancer, including targeted and cellular therapies. Its product pipeline includes PTX-100, PTX-200, OmniCAR, CellPryme-M and CellPryme-A. PTX-100 has completed Phase Ib expansion cohort study in relapsed and refractory T cell lymphomas. PTX-200 is a PH domain inhibitor that inhibits a tumor survival pathway, Akt. OmniCAR is a universal immune receptor platform being developed to enable controllable T-cell activity and multi-antigen targeting with a single-cell product. CellPryme-M technology enhances adoptive cell therapy performance by shifting T and NK cells towards a central memory phenotype, improving persistence, and increasing the ability to find and penetrate tumors. CellPryme-A is an adjuvant therapy designed to be administered to patients alongside cellular immunotherapy to help them overcome a suppressive tumor microenvironment.More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile arrow Created with Sketch.
See benefits
refresh Created with Sketch. REFRESH
Last update - 12.16pm 19/11/2024 (20 minute delay) ?
Day
Open 4.0¢   Day High 4.1¢   Day Low 4.0¢
Daily Volume 558408
Bids   Sellers
Number Price Volume   Number Price Volume
6 3.9¢ 221774   3 4.1¢ 860576

Directors & Senior Management

Mr. Steven Yatomi-Clarke Chief Executive Officer, Managing Director, Executive Director
Ms. Melanie Jaye Leydin Chief Financial Officer, Company Secretary
Mr. Steven B. Engle Non-Executive Chairman of the Board
Dr. James A. Campbell Non-Executive Director
Dr. Allen James Ebens Non-Executive Director
Dr. Ellen Gwen Feigal Non-Executive Independent Director
Dr. Gavin James Shepherd Non-Executive Independent Director

Data source: Refinitiv

(20min delay)
Last
4.0¢ 		Change
0.000(0.00%) 		Mkt cap ! $32.21M
Open High Low Value Volume
4.0¢ 4.1¢ 4.0¢ $22.35K 558.4K

Buyers (Bids)

No. Vol. Price($)
6 221774 3.9¢
 

Sellers (Offers)

Price($) Vol. No.
4.1¢ 860576 3
View Market Depth
Last trade - 14.51pm 19/11/2024 (20 minute delay) ?
Last
4.0¢ 		  Change
0.000 ( 1.27 %)
Open High Low Volume
4.0¢ 4.0¢ 4.0¢ 94998
Last updated 12.16pm 19/11/2024 ?

Top Stories

Things finally 'looking different' for up-and-down Hot Stock tip Stockland

Wealth Within chief analyst Dale Gillham and senior analyst Fil Tortevski have named this week’s HotCopper Hot Stock tip: Real estate group Stockland (ASX:SGP).While Stockland has dipped up and down recently, Mr Tortevski conceded, things are @looking different&CloseCurlyDoubleQuo...
Pan Asia rebranding to 'clear confusion' after bagging $35M for Chile projects Pan Asia Metals has scored $35 million from a New York private equity firm at the same time as the company's big rebrand push begins.
Bigtincan's Board backs Investcorp offer: Why a NASDAQ listing could be game-changing Bigtincan Holdings has fielded an offer from Investcorp. But if you think it's underwhelming – consider Wall Street volumes.
Radiopharm extends radioimmunotherapy trial to 5 more cancer types Radiopharm Theranostics Ltd has received approval to extend its Phase 1 trial of Lu-RAD204 to five more cancer types
To make modern missiles, you need 3D Printing. And in that gold rush, Amaero is selling shovels Put simply: if 3D Printing is a gold rush, Amaero is selling shovels. Or maybe it's more like sneakers in an arms race.
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.